These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25653092)

  • 1. Chronic kidney disease and bone metabolism.
    Kazama JJ; Matsuo K; Iwasaki Y; Fukagawa M
    J Bone Miner Metab; 2015 May; 33(3):245-52. PubMed ID: 25653092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered material properties are responsible for bone fragility in rats with chronic kidney injury.
    Iwasaki Y; Kazama JJ; Yamato H; Matsugaki A; Nakano T; Fukagawa M
    Bone; 2015 Dec; 81():247-254. PubMed ID: 26187196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.
    Iwasaki Y; Kazama JJ; Fukagawa M
    Biomed Res Int; 2017; 2017():3485785. PubMed ID: 28421193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production.
    Liao HW; Huang TH; Chang YH; Liou HH; Chou YH; Sue YM; Hung PH; Chang YT; Ho PC; Tsai KJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM; Schiavi SC
    Semin Dial; 2015; 28(6):578-86. PubMed ID: 26288182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder.
    Costa AG; Bilezikian JP; Lewiecki EM
    Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):324-9. PubMed ID: 26050118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease and fragility fracture.
    Kazama JJ
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):46-52. PubMed ID: 28012057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy.
    Laster M; Pereira RC; Noche K; Gales B; Salusky IB; Albrecht LV
    Nutrients; 2023 Sep; 15(19):. PubMed ID: 37836411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of chronic kidney disease-mineral and bone disorder.
    Mac Way F; Lessard M; Lafage-Proust MH
    Joint Bone Spine; 2012 Dec; 79(6):544-9. PubMed ID: 23177912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of vitamin D deficiency and mild to moderate chronic kidney disease is associated with low bone mineral density and deteriorated femoral microarchitecture: results from the KNHANES 2008-2011.
    Lee YH; Kim JE; Roh YH; Choi HR; Rhee Y; Kang DR; Lim SK
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3879-88. PubMed ID: 24878040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Updates on Lifestyle-Related Diseases and Bone Metabolism. CKD-related osteoporosis].
    Yamada S; Inaba M
    Clin Calcium; 2014 Nov; 24(11):1605-13. PubMed ID: 25355144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disorders of bone and mineral metabolism in CKD: CKD-MBD as a new entity].
    Tsukamoto Y
    Clin Calcium; 2007 May; 17(5):660-4. PubMed ID: 17470993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet.
    Zaloszyc A; Choquet P; Sayeh A; Bartosova M; Schaefer B; Huegel U; Aubertin-Kirch G; Healy C; Severac F; Rizzo S; Boivin G; Schaefer F; Fischbach M; Bacchetta J; Bahram S; Schmitt CP
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis.
    Suzuki T; Mizobuchi M; Yoshida S; Terado N; Aoki S; Sato N; Honda H
    Osteoporos Int; 2022 Dec; 33(12):2649-2652. PubMed ID: 35980440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
    Diniz H; Frazão JM
    Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease and the skeleton.
    Miller PD
    Bone Res; 2014; 2():14044. PubMed ID: 26273531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.
    Pietrzyk B; Smertka M; Chudek J
    Adv Clin Exp Med; 2017 Nov; 26(8):1283-1291. PubMed ID: 29264888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.